Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-12-23

Clinical Trial Update: Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating an anti-PCSK9 antibody in statin-intolerant subjects with hyperlipidemia; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • anti-PCSK9 antibody

Snippet

Sponsor: Amgen | Conditions: Hyperlipidemia | Phase 2 | Status: COMPLETED | Results posted: 2015-12-23